A detailed history of Pallas Capital Advisors LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 21,405 shares of VKTX stock, worth $1.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
21,405
Previous 19,343 10.66%
Holding current value
$1.1 Million
Previous $1.03 Million 32.2%
% of portfolio
0.06%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$49.84 - $70.47 $102,770 - $145,309
2,062 Added 10.66%
21,405 $1.36 Million
Q2 2024

Jul 19, 2024

BUY
$47.39 - $80.2 $209,748 - $354,965
4,426 Added 29.67%
19,343 $1.03 Million
Q1 2024

Apr 15, 2024

BUY
$17.4 - $94.5 $9,587 - $52,069
551 Added 3.84%
14,917 $1.22 Million
Q4 2023

Jan 22, 2024

BUY
$9.24 - $19.64 $8,473 - $18,009
917 Added 6.82%
14,366 $267,000
Q2 2023

Jul 26, 2023

BUY
$14.84 - $24.79 $199,583 - $333,400
13,449 New
13,449 $218,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Pallas Capital Advisors LLC Portfolio

Follow Pallas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pallas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pallas Capital Advisors LLC with notifications on news.